1. Significantly downregulated in NSCLC; low expression correlates with high PD-L1 expression and reduced CD8+T cell infiltration;2. High expression correlates with prolonged PFS; synergistic tumor inhibition with anti-PD-1 therapy. This evidence concerns the gene CD274 and neoplasm.